- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05011526
A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 Against COVID-19 in Adults
A Phase III, Parallel Group, Prospective, Randomized, Double-blind, Active-controlled, Two-arm, Multi-center Study to Evaluate the Immunogenicity, Safety, and Tolerability of MVC-COV1901 Compared to AZD1222 in Adults of 18 Years and Above
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Ciudad del Este, Paraguay
- Hospital Fundación Tesai
-
San Lorenzo, Paraguay
- Hospital de Clinicas - Facultad de Ciencias Médicas, Universidad Nacional de Asunción
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female participant aged 18 years and above at randomization.
- Healthy adults or adults with pre-existing medical conditions who are in stable condition. A stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease 3 months before enrollment and expected to remain stable for the duration of the study.
Female participants:
- A female participant is eligible is the participant is a woman of non-childbearing potential, ie, surgically sterilized or one year post-menopausal.
- If the participant is a woman of childbearing potential, she must agree to practice sexual abstinence or agree to use medically effective contraception from 14 days before screening to 30 days following the last administration of study intervention.
- Have a negative pregnancy test
- Participant is willing and able to comply with all required study visits and follow-up required by this protocol.
- Participant or the participant's legal representative must understand the procedures of the study and provide written informed consent.
Exclusion Criteria:
- Pregnant or breast feeding or have plan to become pregnant within 30 days after the last administration of study intervention.
- Employees at the investigator's site, of the Sponsor or delegate who are directly involved in the conduct of the study.
- Currently receiving or received any investigational intervention within 30 days prior to the first dose of study intervention.
- Administered any licensed live-attenuated vaccines within 28 days or other licensed non-live-attenuated vaccines within 7 days prior to the first dose of study intervention.
- Administered any blood product or intravenous immunoglobulin administration within 12 weeks prior to the first dose of study intervention.
- Currently receiving or anticipate to receive concomitant immunosuppressive or immune-modifying therapy within 12 weeks prior to the first dose of study intervention.
- Currently receiving or anticipate to receive treatment with tumor necrosis factor (TNF)-α inhibitors within 12 weeks prior to the first dose of study intervention.
- Major surgery or any radiation therapy within 12 weeks prior to the first dose of study intervention.
- Has received any other investigational or approved COVID-19 vaccine.
- Immunosuppressive illness or immunodeficient state.
- A history of malignancy with potential risk for recurrence after curative treatment, or current diagnosis of or treatment for cancer.
- Bleeding disorder considered a contraindication to IM injection or phlebotomy.
- Known SARS-CoV-2 infection in the 3 months prior to the first dose of study intervention.
- A history of cerebral venous sinus thrombosis, heparin-induced thrombocytopenia or antiphospholipid syndrome.
- Participant who, in the investigator's judgement, is not in a stable condition and by participating in the study could adversely affect the safety of the participant, interfere with adherence to study requirements or evaluation of any study endpoint.
- A history of hypersensitivity to any vaccine or a history of allergic disease or reactions likely to be exacerbated by any component of the MVC-COV1901 or AZD1222.
- Body (oral, rectal, or ear) temperature ≥ 38.0°C or acute illness within 2 days before the first dose of study intervention.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MVC-COV1901
S-2P protein with CpG and Aluminum Hydroxide/0.5mL
|
Approximately 471 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
|
Experimental: AZD1222
ChAdOx1 nCoV-19 vaccine
|
Approximately 471 participants will receive 2 doses of AZD1222 at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immunogenicity of neutralizing antibody (GMT ratio)
Time Frame: Day 1 to Day 43
|
To demonstrate the immunogenic superiority of MVC-COV1901 to AZD1222 in terms of neutralizing antibody titers at 14 days after the second vaccination -GMT ratio |
Day 1 to Day 43
|
Incidence of Adverse Event within 28 days post the second study intervention
Time Frame: Day 1 to Day 57
|
To evaluate the safety and tolerability of MVC-COV1901 compared to AZD1222 from Day 1 to 28 days after the second vaccination The number and percentage of participants with the occurrence of:
|
Day 1 to Day 57
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immunogenicity of neutralizing antibody (GMT)
Time Frame: Day 29 to Day 209
|
To evaluate the immunogenicity of MVC-COV1901 compared to AZD1222 in terms of neutralizing antibody titers from Day 29 to Day 209 • GMT |
Day 29 to Day 209
|
Immunogenicity of neutralizing antibody(SCR)
Time Frame: Day 29 to Day 209
|
To evaluate the immunogenicity of MVC-COV1901 compared to AZD1222 in terms of neutralizing antibody titers from Day 29 to Day 209 • SCR |
Day 29 to Day 209
|
Immunogenicity of neutralizing antibody(GMT ratio)
Time Frame: Day 29 to Day 209
|
To evaluate the immunogenicity of MVC-COV1901 compared to AZD1222 in terms of neutralizing antibody titers from Day 29 to Day 209 • GMT ratio |
Day 29 to Day 209
|
Incidence of Adverse Event throughout study conduct
Time Frame: Day 1 to 180 days after second vaccination
|
To evaluate the safety of MVC COV1901 compared to AZD1222 over the study period The number and percentage of participants with the occurrence of:
|
Day 1 to 180 days after second vaccination
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of confirmed COVID-19 cases
Time Frame: Day 15 to Day 209
|
To estimate the efficacy of MVC-COV1901, as compared to AZD1222, in the prevention of COVID-19 in terms of :
|
Day 15 to Day 209
|
Immunogenicity of antigen-specific immunoglobulin titers(GMT)
Time Frame: Day 29 to Day 209
|
To evaluate the immunogenicity of MVC-COV1901 compared to AZD1222 in terms of antigen-specific immunoglobulin titers from Day 29 to Day 209 • GMT |
Day 29 to Day 209
|
Immunogenicity of antigen-specific immunoglobulin titers(SCR)
Time Frame: Day 29 to Day 209
|
To evaluate the immunogenicity of MVC-COV1901 compared to AZD1222 in terms of antigen-specific immunoglobulin titers from Day 29 to Day 209 • SCR |
Day 29 to Day 209
|
Immunogenicity of antigen-specific immunoglobulin titers(GMT ratio)
Time Frame: Day 29 to Day 209
|
To evaluate the immunogenicity of MVC-COV1901 compared to AZD1222 in terms of antigen-specific immunoglobulin titers from Day 29 to Day 209 • GMT ratio |
Day 29 to Day 209
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Luis Francisco Armoa Garcia, MD.Ph.D., University of Asuncion
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CT-COV-31
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid19 Vaccine
-
Gamaleya Research Institute of Epidemiology and...Moscow Healthcare DepartmentRecruitingCovid19 | Vaccine Preventable DiseaseRussian Federation
-
National University Hospital, SingaporeAgency for Science, Technology and Research; National University of SingaporeUnknownCovid19 | Breastfeeding | Vaccine Exposure Via Breast MilkSingapore
-
Xavier University of Louisiana.CompletedCovid19 | Vaccine Hesitancy | Vaccine RefusalUnited States
-
Rajavithi HospitalDepartment of Medical servicesWithdrawnCovid19 | Covid19 Vaccine
-
Masaryk UniversityRecruitingAdverse Reaction to Vaccine | COVID19 VaccinePoland, Canada, United States, Croatia, Czechia, Estonia, Ethiopia, Germany, Ghana, Mexico, Portugal, Russian Federation, Serbia, Slovenia
-
Stanford UniversityActive, not recruitingVaccine Hesitancy | Vaccine Refusal | Vaccine KnowledgeKenya
-
Children's Mercy Hospital Kansas CityCompletedVaccine Hesitancy | Vaccine RefusalUnited States
-
University of OttawaNot yet recruitingPneumococcal Vaccine Uptake | Vaccination Willingness | Pneumococcal Vaccine Knowledge | Pneumococcal Vaccine AttitudeCanada
-
PT Bio FarmaCenter for Child Health Universitas Gadjah Mada (CCH-PRO UGM; Cipto Mangunkusumo... and other collaboratorsRecruitingVaccine Adverse Reaction | Vaccine ReactionIndonesia
-
Indiana UniversityMerck Sharp & Dohme LLCCompletedHPV Vaccine Attitudes | HPV Vaccine IntentionUnited States
Clinical Trials on MVC-COV1901
-
Taoyuan General HospitalMedigen Vaccine Biologics Corp.Recruiting
-
Medigen Vaccine Biologics Corp.Completed
-
Medigen Vaccine Biologics Corp.Completed
-
Medigen Vaccine Biologics Corp.Completed
-
Medigen Vaccine Biologics Corp.Coalition for Epidemic Preparedness InnovationsCompleted
-
Medigen Vaccine Biologics Corp.Completed
-
Medigen Vaccine Biologics Corp.CompletedCOVID-19 VaccineParaguay
-
Chang Gung Memorial HospitalMedigen Vaccine Biologics Corp.Active, not recruitingCOVID-19 | Breakthrough InfectionTaiwan
-
Medigen Vaccine Biologics Corp.Completed
-
Medigen Vaccine Biologics Corp.CompletedCovid19 VaccineTaiwan, Vietnam